Dr John Campbell
@campbellteaching·3.3M subscribers·3.1K videos
COVID - 19, Statins and other probable treatments
Posted
June 26, 2020
Views
83,570
Likes
2,478
Comments
878
Engagement
4.02%
June 26, 2020
83,570
2,478
878
4.02%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
24:01Now PlayingTherapeutics
Use of statins is associated with a reduced risk of mortality among individuals with COVID-19 (Cell metabolism, 24 June)
Statins are lipid-lowering therapeutics
Anti-inflammatory effects
Proposed as an adjunct therapy for COVID-19
Retrospective study
N = 13,981 patients with COVID-19
1,219 received statins
28-day all-cause mortality
Statins group = 5.2%
Non-statin group = 9.4%
Hazard ratio 0.58
Imply potential benefits of statin therapy in hospitalized subjects with COVID-19
No indications of increased risk using statins
Many potential confounding factors
Need prospective studies
Need randomized controlled trials
Dexamethasone
Reduced deaths by one third in ventilated patients
Rate ratio 0.65 (p=0.0003)
Reduced deaths by one fifth in patients receiving oxygen only
Rate ratio 0.80 (p=0.0021)
No benefit in patients who did not require respiratory support
Remdesivir
Reduces symptomatic phase from 15 down to 11 days
)310229/fulltext
RECOVERY trial
Large, randomised controlled trial of possible treatments for patients admitted to hospital with COVID-19
11,500 patients have been randomised, 175 NHS hospitals
Lopinavir-Ritonavir
(commonly used to treat HIV)
Low dose Dexamethasone
(a type of steroid, which is typically used to reduce inflammation)
Hydroxychloroquine
(which has now been stopped due to lack of efficacy)
Azithromycin
(a commonly used antibiotic)
Tocilizumab
(an anti-inflammatory treatment given by injection)
Convalescent plasma
(collected from donors who have recovered from COVID-19 and contains
antibodies against the SARS-CoV-2 virus)
India drug
Favipiravir (oral)
Inhibits RNA synthesis
Mumbai, Glenmark Pharmaceuticals
Approvals from Drug Controller General of India
What is Favipiravir?
Approved in Japan for treating influenza
Being tested in 18 clinical trials for Covid-19
Based on Phase-3 data, 2 positive outcomes
For emergency restricted use only for treatment of mild to moderate Covid-19
Every patient must have signed informed consent before treatment initiation
Effects
Clinical improvements of up to 88 % in Covid-19
Rapid reduction in viral load by four days
15 days BD
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
